
OMDA Stock Forecast & Price Target
OMDA Analyst Ratings
Bulls say
Omada Health Inc. reported a remarkable total revenue growth of 49.5% year-over-year, driven by a surge in membership that reached 831,000, significantly surpassing expectations. The company's gross margins expanded to 68.2%, benefiting from an efficient program mix and the integration of AI into its care teams, indicating improved operational efficiencies. Additionally, the forecast suggests continued strong growth with expectations of exceeding 50% revenue growth in FY25, alongside positive EBITDA margin expansion, positioning the company favorably in the evolving cardiometabolic health market.
Bears say
Omada Health Inc. faces a negative outlook primarily due to concerns regarding the sustainability of its growth, particularly as reliance on GLP-1 medications may lead to a slowdown in revenue growth to approximately 20%. Additionally, while the company is investing in a new GLP-1 care track, the anticipated ramp in adjusted EBITDA is expected to decelerate post-2025, complicating its long-term profitability trajectory. Furthermore, increasing competition in the GLP-1 space is placing downward pressure on prices, which may negate cost reductions expected by employers and payors, emphasizing the necessity for enhanced management solutions to optimize delivery.
This aggregate rating is based on analysts' research of Omada Health Inc and is not a guaranteed prediction by Public.com or investment advice.
OMDA Analyst Forecast & Price Prediction
Start investing in OMDA
Order type
Buy in
Order amount
Est. shares
0 shares